Pluvicto®▼, lutetium (177Lu) vipivotide tetraxetan

Description Pluvicto®▼ (lutetium (177Lu) vipivotide tetraxetan) is a radiopharmaceutical solution for infusion.

Indication

Pluvicto®▼ , in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy.

Summary of Product Characteristics (SmPC)

Denmark Finland Iceland Norway Sweden

Practical information about Pluvicto®▼

The representative of the marketing authorisation holder for Pluvicto®▼ is Novartis Sverige AB, tel. +46 8 732 32 00, distributed in the Nordic region by SAM Nordic.

Further information about this medicinal product can be obtained from SAM Nordic,

tel: +46 8 720 58 22, info@samnordic.se

▼This medicinal product is subject to additional monitoring.